Ó£»¨ÊÓƵ

Skip to main content

Table 1 Demographic, pregnancy history and ART treatment characteristics of the study participants

From: The progress of mother-to-child transmission of Human Immunodeficiency Virus (HIV) after Dolutegravir (DTG) optimization program: evidence from a multicenter cohort study in Ethiopia

Variables

Category

Birth cohort year

P-value

2017

2018

2019

2020

2021

2022

Total

Age (years)

N = 1734

15–24

18(32.7)

68(18.2)

72(18)

58(19)

76(22.2)

46(18)

338(19.5)

0.001

25–29

15(27.3)

154(41.2)

136(33.9)

96(31.4)

99(28.9)

83(32.4)

583(33.6)

Ìý

30–34

14(25.5)

95(25.4)

133(33.2)

98(32)

93(27.2)

63(24.6)

496(28.6)

Ìý

>=35

8(14.5)

57(15.2)

60(15)

54(17.6)

74(21.6)

64(25)

317(18.3)

Ìý

Study hospital location

Addis Ababa

41(47.1)

181(34.4)

193(32.5)

141(29.3)

147(31.2)

112(30.9)

815(32.3)

0.000

Oromia

23(26.4)

192(36.5)

204(34.4)

162(33.6)

159(33.8)

108(29.8)

848(33.6)

Ìý

SNNPR

20(23)

103(19.6)

145(24.5)

154(32)

136(28.9)

134(37)

692(27.4)

Ìý

Sidama

3(3.4)

50(9.5)

51(8.6)

25(5.2)

29(6.2)

8(2.2)

166(6.6)

Ìý

levels of hospital care

Primary

0(0)

20(3.8)

58(9.8)

43(8.9)

32(6.8)

40(11)

193(7.7)

0.000

General

11(12.6)

64(12.2)

69(11.6)

74(15.4)

92(19.5)

84(23.2)

394(15.6)

Ìý

Tertiary

76(87.4)

442(84)

466(78.6)

365(75.7)

347(73.7)

238(65.7)

1934(76.7)

Ìý

Gravidity

N = 1928

1

16(29.1)

66(17.4)

91(19.8)

71(18.5)

76(21.1)

62(21.3)

382(19.8)

0.691

2–4

35(63.6)

277(72.9)

319(69.5)

279(72.8)

250(69.4)

198(68)

1358(70.4)

Ìý

>=5

4(7.3)

37(9.7)

49(10.7)

33(8.6)

34(9.4)

31(10.7)

188(9.8)

Ìý

Parity

N = 1928

0

19(34.5)

77(20.3)

98(21.4)

88(23)

85(23.6)

72(24.7)

439(22.8)

0.539

1

18(32.7)

126(33.2)

154(33.6)

118(30.8)

127(35.3)

90(30.9)

633(32.8)

Ìý

2–4

18(32.7)

170(44.7)

194(42.3)

171(44.6)

139(38.6)

124(42.6)

816(42.3)

Ìý

>=5

0(0)

7(1.8)

13(2.8)

6(1.6)

9(2.5)

5(1.7)

40(2.1)

Ìý

PMTCT care enrolment gestation

1st trimester

10(11.5)

50(9.5)

67(11.3)

72(14.9)

47(10)

48(13.3)

294(11.7)

0.000

2nd trimester

21(24.1)

305(58)

344(58)

277(57.5)

239(50.7)

199(55)

1385(54.9)

Ìý

3rd trimester

22(25.3)

76(14.4)

94(15.9)

63(13.1)

97(20.6)

58(16.0)

410(16.3)

Ìý

Term pregnancy

6(6.9)

21(4)

22(3.7)

19(3.9)

20(4.2)

11(3)

99(3.9)

Ìý

Labor and delivery

15(17.2)

31(5.9)

28(4.7)

27(5.6)

32(6.8)

20(5.5)

153(6.1)

Ìý

Postpartum

13(14.9)

43(8.2)

38(6.4)

24(5)

36(7.6)

26(7.2)

180(7.1)

Ìý

WHO stage during enrolment

1

84(96.6)

510(97)

575(97)

473(98.1)

449(95.3)

351(97)

2442(96.9)

0.053

2

3(3.4)

10(1.9)

10(1.7)

4(0.8)

19(4)

10(2.8)

56(2.2)

Ìý

3

0(0)

3(0.6)

7(1.2)

5(1)

3(0.6)

1(0.3)

19(0.8)

Ìý

4

0(0)

3(0.6)

1(0.2)

0(0)

0(0)

0(0)

4(0.4)

Ìý

Partner HIV status

Positive

61(70.1)

398(75.7)

474(79.9)

386(80.1)

381(80.9)

275(76)

1975(78.3)

0.002

Negative

7(8)

47(8.9)

57(9.6)

55(11.4)

44(9.3)

47(13.0)

257(10.2)

Ìý

Unknown

19(21.8)

81(15.4)

62(10.5)

41(8.5)

46(9.8)

40(11)

289(11.5)

Ìý

ART regimens during the PMTCT care

TDF + 3TC + EFV only

63(72.4)

388(73.8)

484(81.6)

263(54.6)

22(4.7)

10(2.8)

1230(48.8)

Ìý

TDF + 3TC + EFV Switched to DTG

0(0)

0(0)

0(0)

75(15.6)

37(7.9)

1(0.3)

113(4.5)

0.000

TDF + 3TC + DTG only

0(0)

0(0)

0(0)

89(18.5)

392(83.2)

342(94.5)

823(32.6)

Ìý

Other ART regimens switched to DTG

0(0)

0(0)

0(0)

8(1.7)

0(0)

0(0)

8(0.3)

Ìý

Other ART regimens only

22(25.3)

135(25.7)

105(17.7)

45(9.3)

20(4.2)

9(2.5)

336(13.3)

Ìý

Other ART regimens switched to EFV

2(2.3)

3(0.6)

4(0.7)

2(0.4)

0(0)

0(0)

11(0.4)

Ìý

ART initiation period

Pre-conception

60(69)

399(75.9)

472(79.6)

396(82.2)

376(79.8)

279(77.1)

1982(78.6)

0.02

1st trimester

2(2.3)

29(5.5)

25(4.2)

15(3.1)

10(2.1)

18(5)

99(3.9)

Ìý

2nd trimester

7(8)

49(9.3)

45(7.6)

36(7.5)

34(7.2)

33(9.1)

204(8.1)

Ìý

3rd trimester

5(5.7)

16(3)

15(2.5)

12(2.5)

23(4.9)

12(3.3)

83(3.3)

Ìý

Labor and delivery

12(13.8)

18(3.4)

22(3.7)

17(3.5)

17(3.6)

11(3)

97(3.8)

Ìý

Postpartum

1(1.1)

15(2.9)

14(2.4)

6(1.2)

11(2.3)

9(2.5)

56(2.2)

Ìý

Mode of delivery

Vaginal delivery

74(85.1)

465(88.4)

505(85.2)

412(85.5)

398(84.5)

304(84)

2158(85.6)

0.034

Emergency CS*

5(5.7)

51(9.7)

66(11.1)

55(11.4)

58(12.3)

40(11)

275(10.9)

Ìý

Elective CS

8(9.2)

10(1.9)

22(3.7)

15(3.1)

14(3)

16(4.4)

85(3.4)

Ìý

Instrumental

0(0)

0(0)

0(0)

0(0)

1(0.2)

2(0.6)

3(0.1)

Ìý

Place of delivery

Study site hospital

76(87.4)

466(88.6)

517(87.2)

428(88.8)

424(90)

328(90.6)

2239(88.8)

0.009

Other healthcare facility

6(6.9)

51(9.7)

66(11.1)

52(10.8)

43(9.1)

32(8.8)

250(9.9)

Ìý

Home delivery

5(5.7)

9(1.7)

10(1.7)

2(0.4)

4(0.8)

2(0.6)

32(1.3)

Ìý

Infant feeding types

N = 2516

Exclusive breastfeeding

85(98.8)

510(97.1)

569(96.1)

458(95.2)

448(95.1)

351(97.2)

2421(96.2)

0.628

Exclusive formula feeding

1(1.2)

14(2.7)

20(3.4)

21(4.4)

22(4.7)

9(2.5)

87(3.5)

Ìý

Mixed-feeding

0(0)

1(0.2)

3(0.5)

2(0.4)

1(0.2)

1(0.3)

8(0.3)

Ìý
  1. TableÌý1 showed the demographic, pregnancy history and ART treatment characteristics of the study participants categorized by the birth cohort years in the selected hospitals in Ethiopia from 2017 to 2022, N = 2521. Bold letters are significant value at P-value of less than 0.05. *ÌýCS means caesarean section.